CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma

Blood

Volumn 124, Issue 12, 2014, Pages 1905-1914

  Azab, Abdel Kareem ^a   Sahin, Ilyas ^a   Azab, Feda ^a,b   Moschetta, Michele ^a   Mishima, Yuji ^a   Burwick, Nicholas ^a   Zimmermann, Johann ^c   Romagnoli, Barbara ^c   Patel, Kalpana ^c   Chevalier, Eric ^c   Roccaro, Aldo M ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Polyphor Ltd   (Switzerland)

Author keywords

AMCs home to tumor sites in MM; CXCR7 inhibition delayed tumor progression in MM through specific regulation of AMC trafficking but not through a direct tumor effect

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; BIOMIMETIC MATERIAL; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER PATIENT; CELL HOMING; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROENVIRONMENT; MONONUCLEAR CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE COURSE; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PLASMA CELL; SCID MOUSE; STEM CELL NICHE; TUMOR CELL LINE; TUMOR EMBOLISM; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; RECEPTORS, CXCR; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84907223851     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558742     Document Type: Article

References (42)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598
2. Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028: 390-399
3. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38(1-2):71-81
4. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5): 1658-1667
5. Ribatti D, Mangialardi G, Vacca A. Antiangiogenic therapeutic approaches in multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):768-775
6. Janic B, Arbab AS. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal. 2010; 10:1088-1099
7. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343-353
8. de la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clin Cancer Res. 2013;19(13): 3360-3368
9. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49(1):219-230
10. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113(18):4341-4351
11. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem. 2005;280(42): 35760-35766
12. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203(9):2201-2213
13. Libert F, Parmentier M, Lefort A, Dumont JE, Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res. 1990;18(7):1917
14. Heesen M, Berman MA, Charest A, Housman D, Gerard C, Dorf ME. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1. Immunogenetics. 1998;47(5): 364-370
15. Sierro F, Biben C, Martínez-Muñoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA. 2007;104(37):14759-14764
16. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA. 2007; 104(40):15735-15740
17. Dai X, Tan Y, Cai S, et al. The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med. 2011; 15(6):1299-1309
18. Yan X, Cai S, Xiong X, et al. Chemokine receptor CXCR7 mediates human endothelial progenitor cells survival, angiogenesis, but not proliferation. J Cell Biochem. 2012;113(4):1437-1446
19. Obrecht D, Chevalier E, Moehle K, Robinson JA. ß-Hairpin protein epitope mimetic technology in drug discovery. Drug Discov Today Technol. 2012;9(1):e63-e69
20. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24): 5782-5794
21. Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6): 1468-1478
22. Azab F, Azab AK, Maiso P, et al. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res. 2012; 18(1):91-104
23. Miller-Kasprzak E, Jagodzínski PP. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz). 2007;55(4):247-259
24. Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? Atherosclerosis. 2006;188(1):12-18
25. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9(6):702-712
26. Moschetta M, Mishima Y, Sahin I, et al. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta. 2014;1846(1):26-39
27. Brennecke P, Arlt MJ, Muff R, et al. Expression of the chemokine receptor CXCR7 in CXCR4- expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice. PLoS ONE. 2013;8(9):e74045
28. Luker KE, Lewin SA, Mihalko LA, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 2012;31(45): 4750-4758
29. Deutsch AJ, Steinbauer E, Hofmann NA, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol. 2013;26(2):182-194
30. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104(4): 1159-1165
31. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503-508
32. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8): 3286-3294
33. Sánchez-Martín L, Sánchez-Mateos P, Cabañas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med. 2013;19(1):12-22
34. Mazzinghi B, Ronconi E, Lazzeri E, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med. 2008;205(2): 479-490
35. Uto-Konomi A, McKibben B, Wirtz J, et al. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun. 2013;431(4):772-776
36. Zabel BA, Wang Y, Lewén S, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009;183(5):3204-3211
37. Cruz-Orengo L, Holman DW, Dorsey D, et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med. 2011;208(2):327-339
38. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest. 2012;92(2): 178-190
39. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013;119(2):339-347
40. Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31-40
41. DiPersio JF, Micallef IN, Stiff PJ, et al; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colonystimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27(28):4767-4773
42. DiPersio JF, Stadtmauer EA, Nademanee A, et al; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23):5720-5726.